DURHAM – Dermatology firm Novan, which hopes to be nearing FDA approval for its lead product compound, is gearing up for a potential launch by acquiring South Carolina-based EPI Health.
The deal could be worth as much as $50 million based on performance and sales. The initial cost for Novan is some $23 million, including $11 million in cash.
Novan calls EPI a “specialty pharmaceutical company” focused on dermatology.
“As we prepare for the planned NDA submission of our lead product candidate, SB206 (berdazimer gel 10.3%), it was imperative that we evaluate a broad spectrum of options for potential commercialization,” said Novan Chair and CEO Paula Brown Stafford.
“This acquisition creates a robust commercial infrastructure for Novan, and I believe sets the stage for the future success of the Company. As of today, we have launched Novan as a fully-integrated specialty dermatology company with a solid pipeline of development candidates complemented by a commercial foundation to further position Novan to realize the value of each.”
Novan noted that EPI Health “has launched and markets innovative prescription therapies to dermatologists to improve the quality of life of patients. EPI Health’s significant product portfolio addresses patient needs across psoriasis, rosacea, dermatosis and acne. Additionally, EPI Health has a seasoned sales force with a proven commercial platform and foundational relationships across the dermatology community.”
